{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:10:53Z","timestamp":1793459453404,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2130,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1111\/j.1365-2133.2009.09329.x","type":"journal-article","created":{"date-parts":[[2009,6,5]],"date-time":"2009-06-05T07:24:06Z","timestamp":1244186646000},"page":"1081-1088","source":"Crossref","is-referenced-by-count":140,"title":["Cytokine imbalance with increased production of interferon-\u03b1 in psoriasiform eruptions associated with antitumour necrosis factor-\u03b1 treatments"],"prefix":"10.1093","volume":"161","author":[{"given":"J.","family":"Seneschal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Milpied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Vergier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lepreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Schaeverbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ta\u00efeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB3","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","article-title":"Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists","volume":"156","author":"Lee","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1345\/aph.1C477","article-title":"Psoriasiform eruption induced by infliximab","volume":"38","author":"Verea","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB6","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","article-title":"Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients","volume":"9","author":"Wollina","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB8","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/path.1721","article-title":"Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus","volume":"205","author":"Wenzel","year":"2005","journal-title":"J Pathol"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1600-0560.2006.00527.x","article-title":"Type I interferon-associated cytotoxic inflammation in lichen planus","volume":"33","author":"Wenzel","year":"2006","journal-title":"J Cutan Pathol"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2340\/00015555-0193","article-title":"Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis","volume":"87","author":"Seneschal","year":"2007","journal-title":"Acta Derm Venereol (Stockh)"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB12","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1034\/j.1600-0854.2002.31003.x","article-title":"Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity","volume":"3","author":"Haller","year":"2002","journal-title":"Traffic"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB13","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/eji.200425885","article-title":"CXCR3 is required for migration to dermal inflammation by normal and in vivo activated T cells: differential requirements by CD4 and CD8 memory subsets","volume":"35","author":"Mohan","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1523-1747.1999.00581.x","article-title":"Human IP-9: a keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10\/Mig receptor (CXCR3)","volume":"112","author":"Tensen","year":"1999","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S","article-title":"Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation","volume":"194","author":"Flier","year":"2001","journal-title":"J Pathol"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1600-0625.2007.00556.x","article-title":"Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches","volume":"16","author":"Wenzel","year":"2007","journal-title":"Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.2005.037424","article-title":"New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists","volume":"65","author":"Kary","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB18","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1038\/jid.2008.96","article-title":"An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in \u2018interface dermatitis\u2019","volume":"128","author":"Wenzel","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/jid.2008.251","article-title":"Chemokines in the pathogenesis of lichenoid tissue reactions","volume":"129","author":"Meller","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/sj.jid.5700945","article-title":"Gene expression profiling of lichen planus reflects CXCL9+-mediated inflammation and distinguishes this disease from atopic dermatitis and psoriasis","volume":"128","author":"Wenzel","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/archderm.143.2.223","article-title":"Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions","volume":"143","author":"de Gannes","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB22","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/archderm.143.12.1593","article-title":"Psoriasiform eruptions during anti TNF-alpha treatment: psoriasis or not?","volume":"143","author":"Seneschal","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11926-007-0075-1","article-title":"Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines","volume":"9","author":"Fitch","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"10.1111\/j.1365-2133.2009.09329.x-BIB25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J Exp Med"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2009.09329.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2009.09329.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:46:05Z","timestamp":1676382365000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/161\/5\/1081\/6642292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09329.x","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}